• Heart Failure
    • Piotr P Ponikowski
    • Piotr P Ponikowski: Influence Statistics

      Piotr P Ponikowski

      Piotr P Ponikowski

      Show email address

      Wroclaw Medical University, Poland (P.P.). | Institute of Heart Diseases, Medical University, Wroclaw, Poland (P.P., J.B.). | Department of Heart Diseases, Wroclaw Medical ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Piotr P Ponikowski:Expert Impact

      Concepts for whichPiotr P Ponikowskihas direct influence:Heart failure,Acute heart failure,Chronic heart failure,Iron deficiency,Patients heart failure,Reduced ejection fraction,Acute heart,Chronic heart.

      Piotr P Ponikowski:KOL impact

      Concepts related to the work of other authors for whichfor which Piotr P Ponikowski has influence:Heart failure,Atrial fibrillation,Blood pressure,Myocardial infarction,Cardiovascular disease,Preserved ejection fraction,Patients hf.

      KOL Resume for Piotr P Ponikowski


      Wroclaw Medical University, Poland (P.P.).

      University Hospital of Würzburg, Würzburg, Germany


      The Cardiology Department, Wroclaw Medical University, Wroclaw, Poland

      Duke University Hospital, Durham, NC, USA

      Wroclaw Medical University.


      Centre for Heart Diseases, University Hospital, Borowska 213, 50-556, Wroclaw, Poland

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Piotr P Ponikowski is among the top experts in the world.
      Concept World rank
      effects rolofylline #1
      introductiontrv027 #1
      hcm ldha #1
      adenosine carotid artery #1
      iqr ivabradine #1
      relax‐ahf study #1
      pre‐discharge bio‐adrenomedullin #1
      biomarker interactions inflammation #1
      empagliflozin exercise ability #1
      deterioration kccq #1
      antagonist rolofylline ahf #1
      discharge octogenarians #1
      acute hf peptides #1
      chf ssmase #1
      ¿un transportador pasivo #1
      impaired hepato‐renal function #1
      95 15 centers #1
      5 dose trv027 #1
      cv88 #1
      trueahf #1
      outpatients cardiologists #1
      eur heart fail #1
      anemia darbepoetin alfa #1
      shf adipose tissue #1
      low natriuresis #1
      blood pressure relaxin #1
      blastahf #1
      swine body weight #1
      relax‐ahf trial #1
      6mwt analysis #1
      4 points 95 #1
      hf chance externality #1
      egfr tertile #1
      swine body weights #1
      10 arm placebo #1
      bmi mrproanp levels #1
      ahf mirnas #1
      acute heart ahf #1
      vericiguat quality #1
      hvr brs #1
      day cardiovascular mortality #1
      ahf patients diabetes #1
      65±13years #1
      patients sbp tertile #1
      placebo serelaxin #1
      patients ferric carboxymaltose #1
      polish landrace pigs #1
      pre‐relax‐ahf #1
      lv male pigs #1
      positive ctnt baseline #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Piotr P Ponikowski

      KOL-Index: 21327

      BACKGROUND: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reduced death and hospitalizations, and improved symptoms in patients with heart failure and reduced ejection fraction. In this ...

      Known for Heart Failure | Reduced Ejection Fraction | Patients Dapagliflozin | Quality Life | Summary Score
      KOL-Index: 18861

      OBJECTIVES: Our purpose was to assess the diagnostic utility of mid-regional pro-atrial natriuretic peptide (MR-proANP) for the diagnosis of acute heart failure (AHF) and the prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with AHF.

      BACKGROUND: There are some caveats and limitations to natriuretic peptide testing in the acute dyspneic patient.

      METHODS: The BACH (Biomarkers in Acute Heart Failure) trial was a prospective, 15-center, international study of 1,641 ...

      Known for Acute Heart Failure | Diagnosis Ahf | Bnp Biomarkers | Atrial Natriuretic | Prognostic Patients
      KOL-Index: 18859

      After acute myocardial infarction, depressed heart rate variability (HRV) has been proven to be a powerful independent predictor of a poor outcome. Although patients with chronic congestive heart failure (CHF) have also markedly impaired HRV, the prognostic value of HRV analysis in these patients remains unknown. The aim of this study was to investigate whether HRV parameters could predict survival in 102 consecutive patients with moderate to severe CHF (90 men, mean age 58 years, New ...

      Known for Independent Predictor | Patients Sdnn | Ventricular Tachycardia | Holter Monitoring | Heart Failure
      KOL-Index: 18761

      BACKGROUND: Serelaxin, recombinant human relaxin-2, is a vasoactive peptide hormone with many biological and haemodynamic effects. In a pilot study, serelaxin was safe and well tolerated with positive clinical outcome signals in patients with acute heart failure. The RELAX-AHF trial tested the hypothesis that serelaxin-treated patients would have greater dyspnoea relief compared with patients treated with standard care and placebo.

      METHODS: RELAX-AHF was an international, double-blind, ...

      Known for Acute Heart Failure | Placebo Serelaxin | Patients Hospital | Recombinant Human | Controlled Trial
      KOL-Index: 18485

      Importance: Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes.

      Objective: To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes.

      Design, Setting, and Participants: Exploratory analysis of a phase 3 randomized trial conducted at 410 sites in 20 countries. Patients with New York ...

      Known for Dapagliflozin Patients | Cardiovascular Death | Heart Failure | Hazard Ratio | Exploratory Analysis
      KOL-Index: 17794

      BACKGROUND: Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure.

      METHODS: AFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and Singapore. Eligible patients were aged 18 years ...

      Known for Ferric Carboxymaltose | Iron Deficiency | Cardiovascular Death | Acute Heart | Placebo 95
      KOL-Index: 17113

      OBJECTIVES: This study sought to assess the effects of rolofylline on renal function in patients with acute heart failure (AHF) and renal dysfunction randomized in PROTECT (Placebo-Controlled Randomized Study of the Selective A(1) Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).

      BACKGROUND: Small studies have indicated that adenosine A(1) receptor ...

      Known for Renal Function | Acute Heart | Volume Overload | Assess Treatment | Patients Hospitalized
      KOL-Index: 16222

      This trial sought to evaluate whether vericiguat, a novel oral soluble guanylate cyclase (sGC) stimulator, was superior to placebo, on a background of standard of care, in increasing the time to the first occurrence of the composite endpoints of cardiovascular (CV) death and heart failure (HF) hospitalization in patients with HF with reduced ejection fraction (HFrEF). Deficiency in sGC-derived cyclic guanosine monophosphate (cGMP) causes both myocardial dysfunction and impaired ...

      Known for Victoria Trial | Efficacy Safety | Patients Vericiguat | Subjects Heart Failure | Cyclase Stimulator
      KOL-Index: 16051

      OBJECTIVES: We tested the hypothesis that intravenous iron improves exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure (CHF) and iron deficiency.

      BACKGROUND: Anemia is common in heart failure. Iron metabolism is disturbed, and administration of iron might improve both symptoms and exercise tolerance.

      METHODS: We randomized 35 patients with CHF (age 64 +/- 13 years, peak oxygen consumption [pVO2] 14.0 +/- 2.7 ml/kg/min) to 16 weeks of intravenous ...

      Known for Anemic Patients | Chronic Heart | Intravenous Iron | Exercise Tolerance | Nyha Functional Class
      KOL-Index: 15997

      BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia.

      METHODS: We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for ...

      Known for Ferric Carboxymaltose | Iron Deficiency | Heart Failure | Patients Anemia | Nyha Functional Class
      KOL-Index: 15932

      Heart failure is a life-threatening disease and addressing it should be considered a global health priority. At present, approximately 26 million people worldwide are living with heart failure. The outlook for such patients is poor, with survival rates worse than those for bowel, breast or prostate cancer. Furthermore, heart failure places great stresses on patients, caregivers and healthcare systems. Demands on healthcare services, in particular, are predicted to increase dramatically ...

      Known for Heart Failure | Patients Caregivers | Improved Outcomes | Healthcare Systems | Awareness Disease
      KOL-Index: 15812

      BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.

      METHODS: We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure ...

      Known for Heart Failure | Sotagliflozin Placebo | Cardiovascular Patients | Hazard Ratio | Urgent Visits
      KOL-Index: 15685

      BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.

      METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat ...

      Known for Heart Failure | Vericiguat Patients | Hazard Ratio | Ejection Fraction | Death Cardiovascular
      KOL-Index: 15370

      Patients admitted for acute heart failure (AHF) experience high rates of in-hospital and post-discharge morbidity and mortality despite current therapies. Serelaxin is recombinant human relaxin-2, a hormone with vasodilatory and end-organ protective effects believed to play a central role in the cardiovascular and renal adaptations of human pregnancy. In the phase 3 RELAX-AHF trial, serelaxin met its primary endpoint of improving dyspnoea through day 5 in patients admitted for AHF. ...

      Known for Acute Heart Failure | Patients Ahf | Whf Day | Standard Therapy | Cardiovascular Mortality
      KOL-Index: 15336

      OBJECTIVES: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.

      BACKGROUND: Many patients with type 2 diabetes mellitus have heart failure and it is important to know about the safety of new treatments for diabetes in these individuals.

      METHODS: Patients 18 to 85 years of age with type 2 diabetes and heart failure (New York Heart Association functional class I to III and left ...

      Known for Heart Failure | Ventricular Function | Diabetes Mellitus | Type 2 | Vildagliptin Patients

      Key People For Heart Failure

      Top KOLs in the world
      John J J V McMurray
      heart failure myocardial infarction atrial fibrillation
      John George Franklin Cleland
      heart failure patients hf atrial fibrillation
      Stephan D Anker
      heart failure iron deficiency cardiac cachexia
      Greegg C Fonarow
      heart failure atrial fibrillation united states
      Karl B Swedberg
      heart failure reduced ejection fraction myocardial infarction
      Piotr P Ponikowski
      heart failure iron deficiency reduced ejection fraction

      Wroclaw Medical University, Poland (P.P.). | Institute of Heart Diseases, Medical University, Wroclaw, Poland (P.P., J.B.). | Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland | University Hospital of Würzburg, Würzburg, Germa

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.